已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and safety of belimumab in IgA nephropathy: real-world evidence

医学 贝里穆马布 蛋白尿 内科学 不利影响 免疫学 蛋白尿 泌尿系统 肾病 红斑狼疮 胃肠病学 回顾性队列研究 队列 单克隆 队列研究 尿 泌尿科 临床试验 肾小球肾炎 系统性红斑狼疮 抗体
作者
Manyi Wu,Yichun Cheng,Xingyang Zhao,Xiaojing Cai,Chunyu Pan,Bowen Qin,Hairui Zhao,Hui Zhang,Han Zhu,Qiaodan Zhou,Xiaoyan Chang,Qingquan Liu,Fang Xiao,Xiaocheng Liu,Shuwang Ge,Junhua Li,Ge Xu
出处
期刊:Nephrology Dialysis Transplantation [Oxford University Press]
标识
DOI:10.1093/ndt/gfag067
摘要

BACKGROUND: Belimumab, a monoclonal antibody targeting B lymphocyte stimulator, has shown benefits in systemic lupus erythematosus and lupus nephritis, but its role in IgA nephropathy (IgAN) remains unclear. We evaluated the effectiveness and safety of belimumab in IgAN. METHODS: This retrospective cohort study included biopsy-proven IgAN patients at Tongji Hospital, China (July 2020-June 2024). 69 patients treated with belimumab were compared with 137 propensity score-matched controls receiving standard therapy. The primary outcome was proteinuria remission, defined as a reduction in 24-hour urinary protein excretion or urine protein-to-creatinine ratio (UPCR) to < 50% of baseline. RESULTS: Among 206 patients with IgAN (median age 37 years, baseline eGFR 79 ml/min/1.73 m², proteinuria 1.1 g/24 h), 173 (84%) achieved proteinuria remission within 12 months. Remission was higher in the belimumab group: 59% vs 46% at 3 months, 77% vs 66% at 6 months, and 93% vs 80% at 12 months (P = 0.025 at 12 months), with lower time-averaged UPCR at 6 months [371 (248 738) vs.463(262 855) mg/g] and 12 months [360 (234 560) vs.433(243 720) mg/g, P = 0.066]. In newly diagnosed patients, remission was significantly higher at 3 months (76.5% vs. 47.1%, P = 0.009) and 6 months (88.2% vs. 67.6%, P = 0.045), with similar trends at later time points. In patients with baseline UPCR >600 mg/g and those receiving RAAS inhibitors, belimumab demonstrated comparable or superior proteinuria reduction. No excess of common adverse events was observed in the belimumab group. CONCLUSION: Belimumab treatment was associated with higher proteinuria remission rates in patients with IgAN, without an increased incidence of common adverse events. These findings suggest that belimumab may represent a superior therapeutic approach for IgAN in real-world clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft的应助被huiliyii采纳,获得10
刚刚
刚刚
FashionBoy的应助被科研通管家采纳,获得10
刚刚
传奇3的应助被科研通管家采纳,获得10
刚刚
香蕉觅云的应助被科研通管家采纳,获得10
1秒前
田様的应助被科研通管家采纳,获得10
1秒前
1秒前
molihuakai的应助被科研通管家采纳,获得10
1秒前
今后的应助被科研通管家采纳,获得10
1秒前
1秒前
彭于晏的应助被科研通管家采纳,获得10
1秒前
1秒前
1秒前
bkagyin的应助被拂晓倩影采纳,获得10
3秒前
3秒前
4秒前
ForTune发布了新的文献求助10
4秒前
kio完成签到 ,获得积分10
5秒前
木头人完成签到 ,获得积分10
5秒前
南风向北发布了新的文献求助10
5秒前
酷波er的应助被SYX采纳,获得10
6秒前
科目三的应助被夏侯乌采纳,获得10
6秒前
桐桐的应助被腼腆的立诚采纳,获得10
6秒前
7秒前
7秒前
今后的应助被111采纳,获得10
8秒前
帝青坤灵完成签到,获得积分10
8秒前
小新star完成签到,获得积分10
9秒前
春风暮雪发布了新的文献求助30
11秒前
初景发布了新的文献求助10
12秒前
12秒前
13秒前
13秒前
14秒前
句号完成签到 ,获得积分10
15秒前
科目三的应助被麻辣小龙虾采纳,获得10
15秒前
16秒前
16秒前
科研通AI6.4的应助被赵曼琳采纳,获得10
18秒前
夏侯乌发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184646
求助须知:如何正确求助?哪些是违规求助? 9573637
关于积分的说明 21832477
捐赠科研通 7781914
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003